Drug Trial Radar · NCT06126653
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Aug 1, 2024
Primary completion
Jan 13, 2025
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- Aardvark Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Center for Psychiatry And Behavioral Medicine Inc.
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 17 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a blinded, placebo controlled, cross-over trial evaluating the safety of two dose-levels of ARD-501 in subjects with ASD.
Conditions
- Autism Spectrum Disorder
Interventions
Low Dose ARD-501Drug
Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.2 mg/kg dosing.
High Dose ARD-501Drug
Titratable, liquid formulation, taken orally. The intervention is given relative to the body weight of the individual. 0.5 mg/kg dosing.
PlaceboDrug
Titratable, liquid formulation, taken orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of the incidence of Treatment-Emergent Adverse Events (TEAE)Time frame: Baseline to Week 5
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Psychiatry and Behavioral Medicine Inc
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.